|
|
Post by sportsrancho on Dec 4, 2020 22:40:15 GMT -5
With no hiccups and the overhang of the debt gone I’d go with 3B.
|
|
|
|
Post by falconquest on Dec 5, 2020 9:54:29 GMT -5
Because so many times revenue has nothing to do with the stock price.. look at the airlines, they’re all going to double, again...having no revenue.. it’s based on a forward-looking prediction. I go by the chart and the chart goes by the past.. the shorts will leave on the run up to FDA approval ..they will come back with a vengeance when the launch starts. IMO We could float up to $4 waiting for the submission. ( If no other news and no other surprises, and no dilution. ) The approvals pretty much guaranteed at least that’s my opinion, so it would be a sell on the news after the run up. That’s my prediction if nothing else happens.. but there’s many theories running around about what the surprises could be and what the possibilities are. I agree with your "forward-looking" comment. That was the basis for my "ability to generate revenue" comment. What Mannkind needs to do is prove they can generate revenue with a Tret approval and then get additional compounds in the pipeline. If Technosphere becomes more well known as a delivery platform then that proves that Mannkind has the ability to generate revenue. That coupled with the expansion of Afrezza sales through VDEX will help drive the share price. It's time for them to move from fledgling to a revenue driven organization. |
|
|
|
Post by mango on Dec 5, 2020 12:34:58 GMT -5
4-8 pps...April through November IMO ..then people will short the launch and wait for proof of revenue. Interesting the most of the posts above set share price to be based on revenue. Also interesting that sports put a $4 pps in April when we are at $3 now. No wonder people thought I was talking nonsense when I set a $10 pps at the end of this year. We may not hit my number this month, but if all developments fall into place soon ... it won't be too long thereafter. But, that's mytakeonit The Domino Effect is coming. TreT Top Line Data Disclosure, Sumatriptan Phase 1, TreT FDA approval, Second UT molecule (could happen before or after approval), Partnership announcement for Sumatriptan, TreT launch, Peds, more pipeline advancements and additions, more partnerships, RLS, and so on. |
|
|
|
Post by sportsrancho on Dec 5, 2020 13:50:29 GMT -5
Because so many times revenue has nothing to do with the stock price.. look at the airlines, they’re all going to double, again...having no revenue.. it’s based on a forward-looking prediction. I go by the chart and the chart goes by the past.. the shorts will leave on the run up to FDA approval ..they will come back with a vengeance when the launch starts. IMO We could float up to $4 waiting for the submission. ( If no other news and no other surprises, and no dilution. ) The approvals pretty much guaranteed at least that’s my opinion, so it would be a sell on the news after the run up. That’s my prediction if nothing else happens.. but there’s many theories running around about what the surprises could be and what the possibilities are. I agree with your "forward-looking" comment. That was the basis for my "ability to generate revenue" comment. What Mannkind needs to do is prove they can generate revenue with a Tret approval and then get additional compounds in the pipeline. If Technosphere becomes more well known as a delivery platform then that proves that Mannkind has the ability to generate revenue. That coupled with the expansion of Afrezza sales through VDEX will help drive the share price. It's time for them to move from fledgling to a revenue driven organization. Exactly ..in the past the market ( pps ) was going on Al Mann’s record and there was a lot of expectation, now we don’t have that. What we have is a failed launch. And a bunch of missed guidance. United therapeutics validates us to a point. Vdex may help validate Afrezza before anyone takes their first hit of TreT🥰 |
|
|
|
Post by mymann on Dec 5, 2020 14:01:11 GMT -5
I really appreciate VDEX. You guys saw something very valuable in Afrezza. I personally got into mnkd because of Technospere.
|
|
|
|
Post by mytakeonit on Dec 5, 2020 14:15:19 GMT -5
With no hiccups and the overhang of the debt gone I’d go with 3B. I'm with sports ... I'd love to make 3B also. But, that's mytakeonit |
|
|
|
Post by casualinvestor on Dec 5, 2020 20:11:45 GMT -5
Profitability of MNKD in total is what will remove the last shadows of the failed launch (the reason for the failed launch does not matter muchnow) from investors minds. I don't think the stock will ever get another massive run up like it did at approval or launch.
But another molecule going to phase 1 sure would help push things up some more.
|
|
|
|
Post by akemp3000 on Dec 5, 2020 21:14:38 GMT -5
IMO...it's just the opposite. A run up is forthcoming. All the history of the CRL, the failure to achieve goals in the past is insignificant history. It's all about the future which appears to be very bright in so many directions. I'm expecting significant announcements and the pps to hit $6 in Q1. Stay tuned. Let's see!
|
|
|
|
Post by sportsrancho on Dec 5, 2020 21:41:37 GMT -5
Who do you think is going to buy the stock for this massive run up?
I’d say it needs to be United therapeutics:-)
|
|
|
|
Post by cretin11 on Dec 5, 2020 22:24:11 GMT -5
Profitability of MNKD in total is what will remove the last shadows of the failed launch (the reason for the failed launch does not matter muchnow) from investors minds. I don't think the stock will ever get another massive run up like it did at approval or launch. But another molecule going to phase 1 sure would help push things up some more. That massive run up at approval seemed like just the beginning. We thought we had a blockbuster on our hands. As you said, the reasons for that failure don’t matter much now. |
|
|
|
Post by longliner on Dec 5, 2020 23:41:39 GMT -5
As Al Mann stated "The three things needed to be successful in business are capital, capital and of course capital." I hope we have enough.....as Mannkind has enough of mine! I now would like some in return. Or, in the proper vernacular, ROI!
|
|
|
|
Post by peppy on Dec 6, 2020 6:32:12 GMT -5
Because so many times revenue has nothing to do with the stock price.. look at the airlines, they’re all going to double, again...having no revenue.. it’s based on a forward-looking prediction. I go by the chart and the chart goes by the past.. the shorts will leave on the run up to FDA approval ..they will come back with a vengeance when the launch starts. IMO We could float up to $4 waiting for the submission. ( If no other news and no other surprises, and no dilution. ) The approvals pretty much guaranteed at least that’s my opinion, so it would be a sell on the news after the run up. That’s my prediction if nothing else happens.. but there’s many theories running around about what the surprises could be and what the possibilities are. |
|
|
|
Post by morfu on Dec 6, 2020 10:34:15 GMT -5
Who do you think is going to buy the stock for this massive run up? I’d say it needs to be United therapeutics:-) I think the market if full of investors still looking where to put their money waiting for positive market signals, Corona was devastating to the economy and entire segments are just uncertain to invest in. If Mannkind can provide stability and prosperity, there will be investors at the current situation.
However, beside a potential run up (since I believe the stock is undervalued at the current situation and even more with a Tret approval) Afrezza promises low and steady long term gain based on the revenue trend over the last 3years, we can expect to gain about 5-10ct earning increase per year from that soon.
Falconchest mentioned VDEX as his wishful source revenue and you pushing more advertisements this week in this forum completely unrelated to Mankind (great for VDEX when they hire a doctor..) ...a clear violation of forum rules!
There is no indication that the Afrezza revenue was in any way impacted by VDEX, as they dont release their numbers, so any bold statements about how they do better than other clinics or are helpful for Mannkind at all currently seems misleading, doesn´t it?
|
|
|
|
Post by sportsrancho on Dec 6, 2020 10:53:03 GMT -5
This is the opportunity of a lifetime or in the last decade to buy undervalued recovery Stocks so I don’t agree with that statement.
I’m pretty sure that Mannkind is glad that we post the news about our clinics.. whether it’s a new one that we are opening, or it’s a great Endo that has come on board. We also need to get the word out about the telemedicine that helps everyone. Harry, Mango and I advertise ( spread the word ) for Mannkind all the time. Although they are not paid for ads in our case or in Mannkind‘s case they are posts from Instagram that are not paid for.
And about Vdex numbers, there are many people that know those numbers, you’re just not one of them.
|
|
|
|
Post by cretin11 on Dec 6, 2020 11:12:15 GMT -5
Who do you think is going to buy the stock for this massive run up? I’d say it needs to be United therapeutics:-) I think the market if full of investors still looking where to put their money waiting for positive market signals, Corona was devastating to the economy and entire segments are just uncertain to invest in. If Mannkind can provide stability and prosperity, there will be investors at the current situation.
However, beside a potential run up (since I believe the stock is undervalued at the current situation and even more with a Tret approval) Afrezza promises low and steady long term gain based on the revenue trend over the last 3years, we can expect to gain about 5-10ct earning increase per year from that soon.
Falconchest mentioned VDEX as his wishful source revenue and you pushing more advertisements this week in this forum completely unrelated to Mankind (great for VDEX when they hire a doctor..) ...a clear violation of forum rules!
There is no indication that the Afrezza revenue was in any way impacted by VDEX, as they dont release their numbers, so any bold statements about how they do better than other clinics or are helpful for Mannkind at all currently seems misleading, doesn´t it? What’s misleading is to imply that VDEX is not helpful to MNKD. Of course VDEX clinics are helpful to MNKD, how could they not be? |
|
